NCT06351371 2026-05-28Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)National Cancer Institute (NCI)Phase 2 Active not recruiting35 enrolled 10 charts